Education
About Us
Working with TipRanks
Follow Us
Deborah Brown Insider Profile
11 Followers
Deborah Brown, Director at Oncolytics Biotech, holds 84.85K shares in Oncolytics Biotech (Ticker: ONCY), holds 200.00K shares in Sernova (Ticker: TSE:SVA), holds 7.45K shares in Cardiol Therapeutics (Ticker: CRDL).
Profitable Transactions
3 out of 3 Profitable Transactions
Average Return
+151.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Deborah Brown holds in companies
Most Profitable Insider Trade
The most profitable trade made by Deborah Brown
Deborah Brown's Trading History
Oncolytics Biotech
Jul 17, 2025
Director
Uninformative Sell
―
$95.88K
Cardiol Therapeutics
May 02, 2020
Director
Informative Buy
24.91K
$7.60K
Sernova
Jul 28, 2022
Director
Uninformative Sell
35.00K
C$28.00K
List of latest transactions for each holding click on a transaction to see Deborah Brown's performance on stock
You May Also Like
Deborah Brown insider profile FAQ
What is the percentage of profitable transactions made by Deborah Brown?
The percentage of profitable transactions made by Deborah Brown is 100%.
What is the average return per transaction made by Deborah Brown?
The average return per transaction made by Deborah Brown is 151.50%.
What stocks does Deborah Brown hold?
Deborah Brown holds: ONCY, CRDL, TSE:SVA stocks.
What was Deborah Brown’s latest transaction?
Deborah Brown latest transaction was an Uninformative Sell of ―.
What was Deborah Brown's most profitable transaction?
Deborah Brown’s most profitable transaction was an Informative Buy of TSE:SVA stock on September 25, 2020. The return on the trade was 364.20%.
What is Deborah Brown's role in Oncolytics Biotech?
Deborah Brown's role in Oncolytics Biotech is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.